Financial Performance - Revenue for the year ended December 31, 2025, was HKD 99,799,000, a decrease of 23.1% from HKD 129,680,000 in 2024[3] - Gross profit for 2025 was HKD 80,264,000, resulting in a gross margin of 80.4%, compared to a gross margin of 69.5% in 2024[3] - Profit before tax for 2025 was HKD 13,987,000, a significant recovery from a loss of HKD 68,031,000 in 2024[3] - The company reported a profit attributable to owners of HKD 13,350,000 for 2025, compared to a loss of HKD 68,338,000 in the previous year[4] - Basic and diluted earnings per share for 2025 were HKD 0.05, a turnaround from a loss per share of HKD 0.28 in 2024[5] - Total comprehensive income for the year was HKD 10,009,000, compared to a total comprehensive loss of HKD 66,170,000 in 2024[5] - The segment performance for footwear products showed a loss of HKD 29,551,000 in 2025, compared to a loss of HKD 39,926,000 in 2024, indicating an improvement in performance[26][27] - The company recorded a pre-tax profit of approximately HKD 14 million for the year, compared to a pre-tax loss of approximately HKD 68 million in 2024, mainly due to gains from asset sales[66] Revenue Breakdown - For the fiscal year ending December 31, 2025, the company reported revenue from footwear sales of HKD 83,562,000, a decrease of 32.9% from HKD 124,455,000 in the previous year[22] - Retail support service revenue increased significantly to HKD 16,237,000 from HKD 5,225,000, marking a growth of 210.5%[22] - The total revenue from Hong Kong for the year ended December 31, 2025, was HKD 89,639,000, a decrease from HKD 112,883,000 in 2024, indicating a decline of approximately 20%[30] - In 2025, the company's footwear business revenue was approximately HKD 99.8 million, a decrease of 23.1% compared to HKD 129.7 million in 2024, primarily due to weak consumer sentiment amid ongoing economic uncertainty[57] Assets and Liabilities - The company's total assets decreased to HKD 71,152,000 in 2025 from HKD 112,154,000 in 2024, primarily due to a reduction in current assets[6] - Non-current liabilities decreased to HKD 3,495,000 in 2025 from HKD 8,465,000 in 2024, reflecting a reduction in employee benefit obligations and lease liabilities[7] - The company has a current liability exceeding current assets by approximately HKD 70,915,000 and total liabilities exceeding total assets by about HKD 54,440,000 as of December 31, 2025[19] - The asset-liability ratio improved to approximately -47.5% as of December 31, 2025, compared to -63.9% in 2024, attributed to the profit recorded during the year[69] Operational Challenges - The company is facing significant uncertainty regarding its ability to continue as a going concern, which may require adjustments to asset valuations and liabilities if it cannot sustain operations[21] - The company has not received any repayments on overdue loans as of the report date, constituting a default event[39] - The company is implementing cost control measures to improve operational cash flow, including close monitoring of sales, distribution costs, and administrative expenses[20] Corporate Governance and Compliance - The company has not applied new accounting standards that are not yet effective, indicating a stable approach to financial reporting[11] - The independent auditor's report did not express an opinion on the group's consolidated financial statements due to significant issues[84] - The group has complied with the corporate governance code, except for the vacancy of the chairman position[79] Asset Sales and Liquidation - The company is in the process of liquidating Shang Ying Medical, which is currently under bankruptcy review, affecting its financial reporting and control over assets[18] - The sale of Shang Ying International Group was completed for a cash consideration of HKD 1, resulting in a net loss of HKD 34,668,000[44] - The sale of Shang Ying Retail Group was completed for a cash consideration of HKD 1, resulting in a net gain of HKD 3,894,000[46] - The sale of Shang Ying Capital Group was completed for a cash consideration of HKD 500,000[48] Employee and Operational Metrics - The company incurred a total of HKD 47,329,000 in employee costs for the year ended December 31, 2025, down from HKD 56,151,000 in 2024[31] - The group employed 108 staff members as of December 31, 2025, a decrease from 111 in the previous year[76] - The company has 31 retail points in Hong Kong and 4 in Macau as of December 31, 2025, an increase from 27 and 3 respectively in 2024[59] Future Outlook and Meetings - The company plans to focus on diversifying its footwear product offerings and exploring potential business collaborations to introduce new brands with growth potential and high margins[58] - The company will hold its annual general meeting on May 20, 2026, to discuss shareholder matters[97] - Share transfer registration will be suspended from May 15, 2026, to May 20, 2026, to determine voting eligibility at the annual general meeting[98]

TATA Health International Holdings Limited TATA 健 康 國 際 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1255） 有關須予披露交易 出售目標公司之 補充公告 茲提述TATA健康國際控股有限公司（「本公司」）日期為二零二六年三月十三日之公 告（「該公告」）。除另有界定外，本公告所用詞彙與該公告所界定者具有相同涵義。 本公司謹此向本公司股東及潛在投資者提供有關出售事項的進一步資料。 有關出售事項的進一步資料 誠如該公告所披露，買方作為貸款人，向KTS HK（目標公司的直接全資附屬公司） 提供20,000,000港元的信貸融資，該融資由(i)KTS HK所持物業的法定押記；(ii) Grand Asian Limited（本集團的間接全資附屬公司）存貨的浮動押記；及(iii)KTS HK的應收款項浮動押記作擔保。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 TATA健康國際 ...

執行董事 張鳴琪 香港，二零二六年三月十六日 董事會會議召開日期 TATA健康國際控股有限公司（「本公司」，及其附屬公司統稱「本集團」）董事（「董 事」）會（「董事會」）宣佈將於二零二六年三月三十一日（星期二）舉行董事會會議，藉 以考慮及批准本集團截至二零二五年十二月三十一日止年度的經審核業績及建議之 末期股息（如有），以及處理其他事項。 承董事會命 TATA健康國際控股有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 TATA Health International Holdings Limited TATA 健 康 國 際 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1255） 於本公告日期，董事會包括一名執行董事：張鳴琪先生；兩名非執行董事：朱俊豪 先生及陳琦先生；及四名獨立非執行董事：黃琳女士、李亮先生、杜建峰先生及 譚開國先生。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 TATA Health International Holdings Limited TATA 健 康 國 際 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1255） 須予披露交易 出售目標公司 出售事項 董事會宣佈，於二零二六年三月十三日，賣方（本公司直接全資附屬公司）與買方 訂立出售協議，據此，賣方有條件同意出售，而買方有條件同意收購銷售股份， 代價為1.00港元。 完成於出售協議日之同日發生，而目標公司不再為本公司的附屬公司，目標集團 的財務業績亦不再併入本集團綜合財務報表。 上市規則之涵義 由於有關出售事項的一項或多項適用百分比率超過5%但均低於25%，根據上市 規則第14章，出售事項構成本公司須予披露交易，須遵守申報及公告規定惟豁免 遵守通函及股東批准規定。 出售事項 – 1 – 董事會宣佈，於二零二六年三月十三日，賣方（本公司直接全資附屬公司）與買方訂 立出售協議， ...

致：香港交易及結算所有限公司 公司名稱: TATA健康國際控股有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2026年3月2日 I. 法定/註冊股本變動 FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01255 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.01 HKD | | 5,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.01 HKD | | 5,000,000 | 本月底法定/註 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 TATA Health International Holdings Limited TATA 健 康 國 際 控 股 有 限 公 司 （於開曼群島註冊成立的有限公司） （股份代號：1255） 有關轉讓契據之 主要及關連交易 及 補救措施 背景 茲提述二零二四年年度業績及復牌公告。誠如二零二四年年度業績及復牌公告所 披露，本公司、眾和、世紀健康及張先生簽署轉讓契據，據此，由於本公司於轉 讓契據日期分別欠付(i)眾和本金總額7,384,916.00港元及(ii)張先生本金總額約 21,939,919.26港元，眾和及張先生各自同意轉讓世紀健康結欠本公司的部分世紀 健康貸款分別為7,384,916.00港元及21,939,919.26港元以按等額基準全額最終結 算本公司結欠眾和及張先生各自的上述未償還金額。 轉讓契據 根據轉讓契據的條款，經計及本公司分別應支付及結欠(i)眾和的本金總額 7,384,916. ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01255 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.01 HKD | | 5,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.01 HKD | | 5,000,000 | 本月底法定/註冊股本總額： HKD 5,000,000 第 1 頁 共 10 頁 v 1.2.0 截至月份: 2026年1月31日 狀態: 新提交 FF301 致：香港交易及結算所有限公司 FF301 公司名稱: ...

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年12月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: TATA健康國際控股有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2026年1月2日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01255 | 說明 | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.01 HKD | | 5,000,000 | | 增加 / 減少 (-) | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.01 HKD | | 5,000,000 | 本月底法定/ ...

Core Viewpoint - TATA Health (01255.HK) resumed trading on December 1 after a 1.5-year suspension, experiencing a significant initial surge of 566.67% to close at HKD 2.00 per share, but subsequently faced a decline, closing at HKD 1.60 on December 12, a drop of 37.50% [1]. Group 1: Company Background - TATA Health, originally known as Hong Kong Retail International Holdings Limited, was listed on the Hong Kong Stock Exchange in 2013, initially focusing on shoe sales, representing brands like Clarks and Josef Seibel, but later shifted its focus to the health sector and financial services [3][5]. - The company has struggled to achieve profitability since its listing, with only three profitable years from 2013 to 2024, accumulating a total net profit of HKD 33.58 million over 12 years, while suffering significant losses, particularly a loss of HKD 152 million in 2020 [6][11]. Group 2: Business Operations - TATA Health's shoe business was primarily focused on the Hong Kong market, relying heavily on tourism, which has been impacted by various factors including political unrest and the COVID-19 pandemic, leading to a 20.1% revenue decline in 2019 compared to 2018 [7][8]. - The company attempted to diversify into the health sector, launching a health app in December 2020 and investing in health-related partnerships, but faced challenges due to a lack of experience and competition in the market [10][11]. Group 3: Financial Performance - TATA Health's financial performance has been poor, with the shoe business generating HKD 124.46 million in revenue but incurring a segment loss of HKD 39.93 million [12]. - The company faced severe operational challenges, leading to a suspension of trading in April 2024 due to the inability to publish its 2023 annual results, with potential delisting risks if it failed to meet the resumption conditions within 18 months [11][13].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年11月30日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: TATA健康國際控股有限公司 (於開曼群島註冊成立的有限公司) 呈交日期: 2025年12月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01255 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 500,000,000 | HKD | | 0.01 | HKD | | 5,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 500,000,000 | HKD | | 0.01 | HKD | | ...